CL2016002083A1 - Composición antifúngica tópica para el tratamiento de onicomicosis - Google Patents

Composición antifúngica tópica para el tratamiento de onicomicosis

Info

Publication number
CL2016002083A1
CL2016002083A1 CL2016002083A CL2016002083A CL2016002083A1 CL 2016002083 A1 CL2016002083 A1 CL 2016002083A1 CL 2016002083 A CL2016002083 A CL 2016002083A CL 2016002083 A CL2016002083 A CL 2016002083A CL 2016002083 A1 CL2016002083 A1 CL 2016002083A1
Authority
CL
Chile
Prior art keywords
treatment
onychomycosis
antifungal composition
topical antifungal
composition
Prior art date
Application number
CL2016002083A
Other languages
English (en)
Inventor
Federico Mailland
Daniela Ceriani
Giuliana Iob
Simone Sarno
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50150638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002083(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of CL2016002083A1 publication Critical patent/CL2016002083A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A61Q3/02—Nail coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

<p>COMPOSICION EN FORMA DE BANIZ DE UÑAS QUE CONSISTE EN CICLOPIROX Y/O AL MENOS UNA SAL DEL MISMO, HIDROXIPROPIL QUITOSANO, AGUA Y AL MENOS UN ALCOHOL C1-C4; Y SU USO PARA EL TRATAMIENTO DE ONICOMICOSIS.</p>
CL2016002083A 2014-02-21 2016-08-18 Composición antifúngica tópica para el tratamiento de onicomicosis CL2016002083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14156113.4A EP2910245A1 (en) 2014-02-21 2014-02-21 Topical antifungal composition for treating onychomycosis

Publications (1)

Publication Number Publication Date
CL2016002083A1 true CL2016002083A1 (es) 2017-06-09

Family

ID=50150638

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002083A CL2016002083A1 (es) 2014-02-21 2016-08-18 Composición antifúngica tópica para el tratamiento de onicomicosis

Country Status (18)

Country Link
US (1) US20170056386A1 (es)
EP (2) EP2910245A1 (es)
JP (1) JP2017506647A (es)
KR (1) KR20160121538A (es)
CN (1) CN106102717A (es)
AR (1) AR099405A1 (es)
AU (1) AU2015220883A1 (es)
CA (1) CA2938922A1 (es)
CL (1) CL2016002083A1 (es)
DO (1) DOP2016000213A (es)
EA (1) EA201691687A1 (es)
IL (1) IL246800A0 (es)
MD (1) MD20160097A2 (es)
MX (1) MX2016010787A (es)
PE (1) PE20161345A1 (es)
PH (1) PH12016501661A1 (es)
UY (1) UY36007A (es)
WO (1) WO2015124586A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106580927A (zh) * 2017-02-17 2017-04-26 中国药科大学 一种环吡酮胺喷膜剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3544983A1 (de) 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
DK0983037T3 (da) 1998-02-09 2003-09-01 Macrochem Corp Fungicid neglelak
US6740326B1 (en) 1998-09-10 2004-05-25 Bioequal Ag Topical nail care compositions
DE10035991A1 (de) * 2000-07-24 2002-02-14 Polichem Sa Nagellackzusammensetzung
EP1958638A1 (en) * 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans to increase nail growth rate

Also Published As

Publication number Publication date
MX2016010787A (es) 2017-04-06
US20170056386A1 (en) 2017-03-02
EP3107528A1 (en) 2016-12-28
DOP2016000213A (es) 2016-11-30
AU2015220883A1 (en) 2016-08-25
IL246800A0 (en) 2016-08-31
AR099405A1 (es) 2016-07-20
KR20160121538A (ko) 2016-10-19
EA201691687A1 (ru) 2016-12-30
EP2910245A1 (en) 2015-08-26
JP2017506647A (ja) 2017-03-09
PH12016501661A1 (en) 2016-10-03
UY36007A (es) 2015-04-30
CN106102717A (zh) 2016-11-09
MD20160097A2 (ro) 2016-12-31
WO2015124586A1 (en) 2015-08-27
CA2938922A1 (en) 2015-08-27
PE20161345A1 (es) 2016-12-17

Similar Documents

Publication Publication Date Title
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2016002971A1 (es) Combinación.
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
AR102203A1 (es) Composiciones para el cuidado oral que comprenden zinc, arginina y serina
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2016001546A1 (es) Composición para el cuidado oral que comprende serina y al menos una sal de zinc.
CL2013003198A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
EA201890212A1 (ru) Новое применение сульфата декстрана
CL2013002193A1 (es) Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CL2015003352A1 (es) Composiciones antitranspirantes
AR101581A1 (es) Composición de colutorio
CL2015002191A1 (es) Composición antifúngica tópica para el tratamiento de onicomicosis.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
CU20150176A7 (es) Derivados de prodroga de triazolpiridinas sustituídas
CO2018001831A2 (es) Composición de absorción percutánea en forma de parche
ES2759940T8 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer